Phase Ib/II clinical trial of ruxolitinib in combination with nilotinib and prednisona for myelofibrosis: RuNiC study

Trial Profile

Phase Ib/II clinical trial of ruxolitinib in combination with nilotinib and prednisona for myelofibrosis: RuNiC study

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Nilotinib (Primary) ; Prednisone (Primary) ; Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions
  • Acronyms RuNiC
  • Most Recent Events

    • 18 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top